The Microbiome Business & Science Briefing
MicrobimeTimes
Reporting on The Latest Microbiome Business & Scientific Developments
TRENDING
Prokarium: Leading the Evolution of Bacterial Immunotherapy, the Next Frontier in Cancer Treatment• Claude Discovers Novel Enzyme System with CRISPR-like Repeats• New Clinical Study Aims to Find Out if FMT capsules could help better manage anorexia• MaaT Pharma Provides Update on MaaT013 (Xervyteg®) Potential Development Plan Following CHMP Negative Opinion After Re-examination• Evvy Raises $40M Series B to Scale AI-Powered Precision Diagnostics & Care Platform for Women’s Health• Armata Pharmaceuticals Receives U.S. FDA Breakthrough Therapy Designation for AP-SA02•

All News

Biomica Announces Closing of $20 Million Financing Round
Finance

Biomica Announces Closing of $20 Million Financing Round

APR 27, 2023
Seres Therapeutics and Nestlé Health Science Announce FDA Approval of VOWST™
Editor's Choice

Seres Therapeutics and Nestlé Health Science Announce FDA Approval of VOWST™

APR 27, 2023
Vedanta Biosciences Announces $106.5 Million Financing to Advance Pipeline of Defined Bacterial Consortia Therapies
Editor's Choice

Vedanta Biosciences Announces $106.5 Million Financing to Advance Pipeline of Defined Bacterial Consortia Therapies

APR 25, 2023
DSM agrees terms to acquire postbiotics pioneer Adare Biome
Biotics and Supplements

DSM agrees terms to acquire postbiotics pioneer Adare Biome

APR 19, 2023
Vedanta Biosciences Publishes Phase 2 Results
Clinical & Manufacturing

Vedanta Biosciences Publishes Phase 2 Results

APR 18, 2023
Microbiotica Announces Clinical Trial Collaboration with MSD
Clinical & Manufacturing

Microbiotica Announces Clinical Trial Collaboration with MSD

APR 13, 2023
Metagen Therapeutics Raises Over 8M $ in Initial Closing of Series A
Finance

Metagen Therapeutics Raises Over 8M $ in Initial Closing of Series A

APR 12, 2023
Researchers create virus-resistant, safely restrained E. coli
Editor's Choice

Researchers create virus-resistant, safely restrained E. coli

APR 10, 2023
Aurealis therapeutics raises $10 million in an oversubscribed series A financing
Finance

Aurealis therapeutics raises $10 million in an oversubscribed series A financing

APR 3, 2023
Human body a breeding ground for antimicrobial resistance genes
Infectious Disease & AMR

Human body a breeding ground for antimicrobial resistance genes

MAR 31, 2023
IFF Achieves Industrial Scale Production of a Strict Anaerobic ‘Next Generation’ Probiotic Strain
Biotics and Supplements

IFF Achieves Industrial Scale Production of a Strict Anaerobic ‘Next Generation’ Probiotic Strain

MAR 30, 2023